Corticosteroid Therapy
Long-Acting β-agonist/Inhaled Corticosteroid Therapy and Asthma Mortality Pharmacoepidemiological Study of Long-Acting β-agonist or Inhaled Corticosteroid Therapy and Asthma Mortality: Clinical Implications Clinical Drug Investigation 2016 The increased risk of asthma mortality in association with long-acting β2-agonist (LABA) monotherapy is well documented but the risk associated with LABA plus inhaled corticosteroid (ICS) therapy remains unclear. We […]
Asthma inhalers as a treatment for COVID19
QUT mathematician, physician and Australian Research Council Future Fellow, Associate Professor Dan Nicolau, is a lead researcher in the STOIC ( STerOids In COVID19 ) trial. The trial is looking at whether asthma inhalers given to people with early stage COVID19 can reduce progression of respiratory illness and cut emergency department presentations and hospital admissions. […]
Add-on tiotropium
Add-on tiotropium versus step-up inhaled corticosteroid plus long-acting beta-2‐agonist in real-world patients with asthma Allergy and Asthma Proceedings, 2020 A step-up approach (increasing inhaled corticosteroid [ICS] dose and/or add-on treatment) is recommended for asthma that is uncontrolled despite ICS plus long-acting beta-2‐agonist (LABA) combination treatment. Understanding the impact of different treatment options on health outcomes […]
Inhaled steroids reduce ACE2 expression lungs
As the COVID19 pandemic spreads across the world, its primary manifestation in severe or critical disease remains respiratory, beginning with pneumonitis, progressing through acute respiratory distress syndrome to terminal respiratory failure. At present, therefore, people who already have chronic lung disease, including asthma and chronic obstructive pulmonary disease (COPD), are at very high risk for […]
Asthma inhalers being trialed for treatment of COVID19
Researchers from Queensland University of Technology and Oxford University are working in collaboration to begin human clinical trials of inhaled corticosteroids, commonly used for asthma patients, on patients with COVID19. The researchers believe that this could be useful for patients with the novel coronavirus infection. The COVID19 pandemic The novel coronavirus or severe acute respiratory […]
Asthma inhalers may suppress children’s growth
Corticosteroid drugs that are given by inhalers to children with asthma may suppress their growth, evidence suggests. Two new systematic reviews published in The Cochrane Library focus on the effects of inhaled corticosteroid drugs (ICS) on growth rates. The authors found children’s growth slowed in the first year of treatment, although the effects were minimised […]
Asthma does not appear to increase the risk of COVID19
Asthma does not appear to increase the risk of COVID19 Older age and conditions such as heart disease, high blood pressure, chronic obstructive pulmonary disease, diabetes and obesity are reported risk factors for the development and progression of COVID19. Older age and conditions such as heart disease, high blood pressure, chronic obstructive pulmonary disease, diabetes […]
Asthma At A Glance
Asthma is a chronic inflammatory disease characterized by recurrent respiratory symptoms such as breathlessness, cough, and wheezing as well as chest tightness. In normal conditions, the air is free to move within our lungs through a complex conductive system also called airways. In specific conditions and when asthmatic patient conditions are uncontrolled, the airways are […]
Treatment of asthma
Budesonide/salmeterol in fixed-dose combination for the treatment of asthma Fixed-dose combinations (FDC) of inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) are well established in asthma treatment. The budesonide/salmeterol (B/S) FDC is now about to reach the market. It is provided as a powder in hard capsules of two strengths: 120/20μg and 240/20μg when expressed as […]
Treatment comparison of budesonide with salmeterol
Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged > or =16 years with asthma: post hoc analysis of a randomized, double-blind study Affiliations Three fixed maintenance-dose inhaled corticosteroid/long-acting beta(2)-agonist (ICS/LABA) combinations for the treatment of asthma are currently available: salmeterol/fluticasone propionate (Seretide/Advair/Adoair) budesonide/formoterol (Symbicort) and beclometasone/formoterol (Foster). All of these combinations have proven […]